Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii545-viii545 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii545 |
|---|---|
| container_issue | |
| container_start_page | viii545 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Grohe, C. Zander, I. Lüdtke-Heckenkamp, K. Blau, W. Krüger, S. Franke, C. Mueller-Huesmann, H. Brückl, W.M. Basara, N. Ukena, D. Lang, S. Atz, J. Kaiser, R. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy292.125 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy292_125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419499158</els_id><sourcerecordid>32137422</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2785-c673d350e3264b4207af36c7ca846d1d8a6a33b2302f64a52f05fe7b70907ae63</originalsourceid><addsrcrecordid>eNp9kc1q3DAUhUVpSaZJHqCbomUDdaIfWx43q2HaTgLDBPLTrbmWrouKLRvJYzIP2PeKjNuQVVZa3O8cnXsPIZ84u-CskJfgXOf0ZWsOohAXXGTvyIJnqkiWLOXvyYIVQiZ5JtNj8jGEP4wxVYjiiBxLwWWeCrEgf3fWDWjA2Yr2zT5Q02kc4Akbah313X6wDqlurLMaGtp70IPV-I3-Wt1tVt9vv1KgG_QtuDjrQo9xPCKNuZLJ2I_oBtu5KA3D3hzol93N_Tn1WDcT6X6_fDF4hKGNNNWdM3YShSlCNMaxa8aJ3d2vt-tXZAPOBA09npIPNTQBz_69J-Tx54-H9XWyvd3crFfbRIt8mSVa5dLIjKEUKq1SwXKopdK5hmWqDDdLUCBlJSQTtUohEzXLasyrnBURRSVPCJ99ddw1xC3K3tsW_KHkrJwqKedKyrmSMlYSNZ9nTb-vWjQviv8dROBqBjAmHy36MmiLTqOxPh6pNJ19w_4ZVwGjCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Grohe, C. ; Zander, I. ; Lüdtke-Heckenkamp, K. ; Blau, W. ; Krüger, S. ; Franke, C. ; Mueller-Huesmann, H. ; Brückl, W.M. ; Basara, N. ; Ukena, D. ; Lang, S. ; Atz, J. ; Kaiser, R.</creator><creatorcontrib>Grohe, C. ; Zander, I. ; Lüdtke-Heckenkamp, K. ; Blau, W. ; Krüger, S. ; Franke, C. ; Mueller-Huesmann, H. ; Brückl, W.M. ; Basara, N. ; Ukena, D. ; Lang, S. ; Atz, J. ; Kaiser, R.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy292.125</identifier><identifier>PMID: 32137422</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii545-viii545</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2785-c673d350e3264b4207af36c7ca846d1d8a6a33b2302f64a52f05fe7b70907ae63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32137422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grohe, C.</creatorcontrib><creatorcontrib>Zander, I.</creatorcontrib><creatorcontrib>Lüdtke-Heckenkamp, K.</creatorcontrib><creatorcontrib>Blau, W.</creatorcontrib><creatorcontrib>Krüger, S.</creatorcontrib><creatorcontrib>Franke, C.</creatorcontrib><creatorcontrib>Mueller-Huesmann, H.</creatorcontrib><creatorcontrib>Brückl, W.M.</creatorcontrib><creatorcontrib>Basara, N.</creatorcontrib><creatorcontrib>Ukena, D.</creatorcontrib><creatorcontrib>Lang, S.</creatorcontrib><creatorcontrib>Atz, J.</creatorcontrib><creatorcontrib>Kaiser, R.</creatorcontrib><title>Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1q3DAUhUVpSaZJHqCbomUDdaIfWx43q2HaTgLDBPLTrbmWrouKLRvJYzIP2PeKjNuQVVZa3O8cnXsPIZ84u-CskJfgXOf0ZWsOohAXXGTvyIJnqkiWLOXvyYIVQiZ5JtNj8jGEP4wxVYjiiBxLwWWeCrEgf3fWDWjA2Yr2zT5Q02kc4Akbah313X6wDqlurLMaGtp70IPV-I3-Wt1tVt9vv1KgG_QtuDjrQo9xPCKNuZLJ2I_oBtu5KA3D3hzol93N_Tn1WDcT6X6_fDF4hKGNNNWdM3YShSlCNMaxa8aJ3d2vt-tXZAPOBA09npIPNTQBz_69J-Tx54-H9XWyvd3crFfbRIt8mSVa5dLIjKEUKq1SwXKopdK5hmWqDDdLUCBlJSQTtUohEzXLasyrnBURRSVPCJ99ddw1xC3K3tsW_KHkrJwqKedKyrmSMlYSNZ9nTb-vWjQviv8dROBqBjAmHy36MmiLTqOxPh6pNJ19w_4ZVwGjCw</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Grohe, C.</creator><creator>Zander, I.</creator><creator>Lüdtke-Heckenkamp, K.</creator><creator>Blau, W.</creator><creator>Krüger, S.</creator><creator>Franke, C.</creator><creator>Mueller-Huesmann, H.</creator><creator>Brückl, W.M.</creator><creator>Basara, N.</creator><creator>Ukena, D.</creator><creator>Lang, S.</creator><creator>Atz, J.</creator><creator>Kaiser, R.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape</title><author>Grohe, C. ; Zander, I. ; Lüdtke-Heckenkamp, K. ; Blau, W. ; Krüger, S. ; Franke, C. ; Mueller-Huesmann, H. ; Brückl, W.M. ; Basara, N. ; Ukena, D. ; Lang, S. ; Atz, J. ; Kaiser, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2785-c673d350e3264b4207af36c7ca846d1d8a6a33b2302f64a52f05fe7b70907ae63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grohe, C.</creatorcontrib><creatorcontrib>Zander, I.</creatorcontrib><creatorcontrib>Lüdtke-Heckenkamp, K.</creatorcontrib><creatorcontrib>Blau, W.</creatorcontrib><creatorcontrib>Krüger, S.</creatorcontrib><creatorcontrib>Franke, C.</creatorcontrib><creatorcontrib>Mueller-Huesmann, H.</creatorcontrib><creatorcontrib>Brückl, W.M.</creatorcontrib><creatorcontrib>Basara, N.</creatorcontrib><creatorcontrib>Ukena, D.</creatorcontrib><creatorcontrib>Lang, S.</creatorcontrib><creatorcontrib>Atz, J.</creatorcontrib><creatorcontrib>Kaiser, R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grohe, C.</au><au>Zander, I.</au><au>Lüdtke-Heckenkamp, K.</au><au>Blau, W.</au><au>Krüger, S.</au><au>Franke, C.</au><au>Mueller-Huesmann, H.</au><au>Brückl, W.M.</au><au>Basara, N.</au><au>Ukena, D.</au><au>Lang, S.</au><au>Atz, J.</au><au>Kaiser, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii545</spage><epage>viii545</epage><pages>viii545-viii545</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32137422</pmid><doi>10.1093/annonc/mdy292.125</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii545-viii545 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy292_125 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Nintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A30%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nintedanib%20plus%20docetaxel%20in%20routine%20clinical%20practice:%20VARGADO,%20a%20German%20prospective%20non-interventional%20study%20(NIS)%20reflecting%20routine%20treatment%20conditions%20in%20an%20evolving%20NSCLC%20treatment%20landscape&rft.jtitle=Annals%20of%20oncology&rft.au=Grohe,%20C.&rft.date=2018-10&rft.volume=29&rft.spage=viii545&rft.epage=viii545&rft.pages=viii545-viii545&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy292.125&rft_dat=%3Cpubmed_cross%3E32137422%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32137422&rft_els_id=S0923753419499158&rfr_iscdi=true |